{
  "url": "https://openlegislation.uk/human-medicines-regulations-2012/schedule-19/paragraph-wrapper7n1",
  "json_url": "https://openlegislation.uk/human-medicines-regulations-2012/schedule-19/paragraph-wrapper7n1.json",
  "legislation": "uksi/2012/1916",
  "legislation_title": "The Human Medicines Regulations 2012",
  "legislation_url": "https://openlegislation.uk/human-medicines-regulations-2012",
  "path": "schedule/19/paragraph/wrapper7n1",
  "kind": "paragraph",
  "number": null,
  "heading": null,
  "text": "Adrenaline 1:1000 up to 1mg for intramuscular use in anaphylaxis\nAtropine sulphate and obidoxime chloride injection\nAtropine sulphate and pralidoxime chloride injection\nAtropine sulphate injection\nAtropine sulphate, pralidoxime mesilate and avizafone injection\nChlorphenamine injection\nDicobalt edetate injection\nGlucagon injection\nGlucose injection\nHydrocortisone injection\nNaloxone products\nPralidoxime chloride injection\nPralidoxime mesilate injection\nPromethazine hydrochloride injection\nSnake venom antiserum\nSodium nitrite injection\nSodium thiosulphate injection\nSterile pralidoxime",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Words in Sch. 19 substituted (2.12.2024) by The Human Medicines (Amendments Relating to Naloxone and Transfers of Functions) Regulations 2024 (S.I. 2024/1125), regs. 1(2), 12"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2012/1916/schedule/19/paragraph/wrapper7n1",
    "retrieved_at": "2026-10-29T01:24:34.993203+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}